GlassScriptPhysician profile
Oladele A Adebogun
NPI 1104822097
$36,955.40
in general payments reported to CMS, 2019-2025
47 companies · $6,110 in 2025
The $6,110 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,312 · 2020: $3,155 · 2021: $4,700 · 2022: $4,271 · 2023: $6,509 · 2024: $5,898 · 2025: $6,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $34.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,482.65 |
| Education | $34.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $7,047.71 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,132.14 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $2,348.00 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $2,347.36 | 2021-2025 | Vraylar |
| Corium, LLC | $2,150.02 | 2021-2025 | Azstarys, Azstarys |
| Tris Pharma INC | $1,890.62 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Takeda Pharmaceuticals U.S.A., INC. | $1,860.14 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $1,583.54 | 2019-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $1,369.19 | 2019-2024 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $1,366.20 | 2020-2025 | Lybalvi, Aristada, Vivitrol |
| Sunovion Pharmaceuticals INC. | $1,278.18 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $1,126.68 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $1,124.36 | 2019-2020 | |
| Lundbeck LLC | $939.77 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $853.31 | 2022-2025 | Auvelity, Sunosi |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $812.82 | 2019-2025 | Adzenys Xr-Odt, Metadate Cd, Cotempla Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $790.24 | 2024-2025 | Cobenfy |
| Validus Pharmaceuticals LLC | $633.56 | 2019-2025 | Raldesy, Equetro, Equetro |
| Indivior INC. | $519.96 | 2020-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $493.03 | 2019-2023 | Ingrezza |
| Noven Therapeutics, LLC | $479.63 | 2020-2025 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $332.33 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $322.56 | 2019-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $285.95 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $216.97 | 2021-2025 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $204.70 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $155.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $145.33 | 2020-2023 | Belsomra |
| Almatica Pharma LLC | $135.31 | 2022-2024 | Loreev Xr |
| Neuronetics, INC. | $135.20 | 2019-2024 | Neurostar Tms Therapy System |
| Eisai INC. | $132.91 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $123.36 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $115.57 | 2019-2025 | Relexxii |
| Adlon Therapeutics L.P. | $102.55 | 2019-2021 | |
| Shire North American Group INC | $69.51 | 2019 | |
| Livanova USA, INC. | $63.94 | 2020-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Soleno Therapeutics, INC. | $57.18 | 2025 | Vykat Xr |
| Avion Pharmaceuticals | $51.67 | 2023 | Methylphenidate Hydrochloride |
| Owp Pharmaceuticals, INC. | $26.32 | 2019-2020 | |
| Braeburn INC. | $22.11 | 2023 | Brixadi |
| Acadia Pharmaceuticals INC | $20.68 | 2021 | |
| Tempus Ai, INC | $17.59 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.73 | 2025 | |
| Alfasigma USA, INC. | $14.85 | 2021 | |
| Sage Therapeutics, LLC | $14.15 | 2021 | |
| Biogen, INC. | $13.61 | 2024 | Vumerity |
| Azurity Pharmaceuticals, INC. | $13.56 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oladele Adebogun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.